Decipher Labs standalone sales fall to zero in September

Decipher Labs Limited reported zero standalone revenue from operations in the quarter ended 30 September 2026, as pharmaceutical manufacturing and trading and consultancy services each recorded no sales; the company posted a Rs 13.69 lakh net loss, compared with a Rs 11.56 lakh loss a year earlier.

Why did Decipher Labs report zero standalone revenue?

Decipher Labs reported no standalone sales in the September 2026 quarter because both disclosed operating segments recorded revenue of Rs 0.00 lakh. Total revenue from operations was consequently Rs 0.00 lakh, down from Rs 9.81 lakh in the June 2026 quarter and Rs 8.80 lakh in the September 2025 quarter.

The filing identifies two standalone segments: manufacturing and trading of pharmaceutical drugs, and consultancy services. Pharmaceutical manufacturing and trading reported no revenue in September 2026, unchanged from the June 2026 quarter, while consultancy services fell from Rs 9.41 lakh in June to Rs 0.00 lakh. Consultancy services had reported Rs 8.80 lakh of sales in the September 2025 quarter.

The half-year result shows that Decipher Labs' Rs 9.81 lakh of standalone revenue for the six months ended 30 September 2026 was generated in the preceding June quarter. Revenue for the comparable six months ended 30 September 2025 was Rs 93.45 lakh, while revenue for the year ended 31 March 2026 was Rs 113.54 lakh.

How did Decipher Labs' standalone loss change in September?

Decipher Labs' standalone net loss widened to Rs 13.69 lakh in the September 2026 quarter from Rs 7.92 lakh in June 2026 and Rs 11.56 lakh in September 2025. The loss before tax was Rs 13.57 lakh, and deferred tax expense of Rs 0.12 lakh brought the reported loss to Rs 13.69 lakh.

Total expenses fell to Rs 13.56 lakh from Rs 17.69 lakh in the June 2026 quarter and Rs 20.50 lakh a year earlier, but exceeded the quarter's nil income. Employee benefits expense was Rs 5.44 lakh, depreciation was Rs 0.45 lakh and other expenses were Rs 7.67 lakh during the September quarter.

For the half year ended 30 September 2026, Decipher Labs posted a standalone net loss of Rs 21.61 lakh, compared with a Rs 5.97 lakh loss in the corresponding 2025 period. Half-year employee benefits expense rose to Rs 10.93 lakh from Rs 7.70 lakh, while other expenses declined to Rs 19.02 lakh from Rs 26.42 lakh.

Which Decipher Labs segments reported losses?

Decipher Labs reported losses in both standalone segments during the September 2026 quarter: Rs 10.55 lakh in pharmaceutical manufacturing and trading and Rs 13.02 lakh in consultancy services. These segment results are stated before tax and interest, and their combined Rs 13.57 lakh loss matched the reported standalone loss before tax because the filing showed no interest or exceptional items.

Consultancy services' segment loss increased from Rs 7.56 lakh in the June 2026 quarter and Rs 2.79 lakh in the September 2025 quarter, as its quarterly sales fell to nil. Pharmaceutical manufacturing and trading recorded a Rs 10.32 lakh segment loss in June 2026 and a Rs 8.89 lakh loss a year earlier, despite recording no quarterly sales in each comparison.

For the six months ended 30 September 2026, pharmaceutical manufacturing and trading recorded a segment loss of Rs 10.57 lakh, while consultancy services recorded a Rs 20.58 lakh loss. In the corresponding 2025 half year, the respective segment losses were Rs 1.08 lakh and Rs 1.57 lakh, when pharmaceutical revenue was Rs 67.50 lakh and consultancy revenue was Rs 25.95 lakh.

What do Decipher Labs' standalone cash flow and borrowings show?

Decipher Labs used Rs 22.78 lakh in operating activities during the half year ended 30 September 2026, compared with Rs 28.42 lakh used in the year ended 31 March 2026. The half-year operating outflow followed a Rs 21.45 lakh loss before tax and included a Rs 5.20 lakh increase in trade receivables and a Rs 3.90 lakh increase in other assets.

Financing activities generated Rs 21.10 lakh in the six-month period through increased borrowings. Standalone current borrowings were Rs 71.42 lakh at 30 September 2026, up from Rs 50.32 lakh at 31 March 2026, while cash and cash equivalents fell to Rs 0.82 lakh from Rs 2.50 lakh over the same dates.

The standalone balance sheet reported total assets of Rs 9.05 crore at 30 September 2026, compared with Rs 9.00 crore at 31 March 2026. Investments were unchanged at Rs 8.66 crore, trade receivables rose to Rs 8.59 lakh from Rs 3.39 lakh, and other equity was negative Rs 2.08 crore compared with negative Rs 1.86 crore at the March year end.

Conclusion

The September 2026 standalone results show that Decipher Labs had no sales in either operating segment while its Rs 13.69 lakh quarterly net loss exceeded the Rs 7.92 lakh loss in June 2026 and the Rs 11.56 lakh loss a year earlier. First-half revenue of Rs 9.81 lakh was also substantially below the Rs 93.45 lakh reported in the corresponding 2025 period.

The next disclosed matter to watch is whether Decipher Labs resumes sales in either segment and whether operating cash use continues to be financed through borrowings, which rose by Rs 21.10 lakh in the first half. The company also said the four New Labour Codes, effective from 21 November 2025, resulted in no estimated liability for its own employees, while it continues to evaluate possible effects for its contract workforce.